Improving cardiovascular health of patients with chronic kidney disease
The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning
medication, would reduce cardiovascular death or major cardiovascular events
in patients with advanced stages of chronic kidney disease.
New paper from @PHRIresearch – Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvac023/6564176#.YljfvOxWV9k.twitter #CardioTwitter